Is there a rationale for aggressive breast cancer liver metastases resections in Polish female patients? Analysis of overall survival following hepatic resection at a single centre in Poland

Eliza Kobryń 1, Konrad Kobryń 1, Tadeusz Wróblewski 1, Krzysztof Kobryń 1, Radosław Pietrzak 1, Paweł Rykowski 1, Bogna Ziarkiewicz-Wróblewska 2, Krzysztof Lamparski 3, Krzysztof Zieniewicz 1, Waldemar Patkowski 1, Marek Krawczyk 1, Rafał Paluszkiewicz 1
1 - Department of General, Transplant and Liver Surgery, Medical University, Warsaw, Poland
2 - Department of Pathology, Medical University, Warsaw, Poland
3 - Department of Radiology, Medical University, Warsaw, Poland
Ann Agric Environ Med
2016; 23 (4):
ICID: 1226866
Article type: Original article
 
 
Introduction. Breast cancer (BC) makes up nearly 26% of malignant tumours worldwide and is the leading cause of cancer-related deaths in European women. With approximately 18,000 new cases of BC diagnosed in Polish women annually, breast cancer liver metastasis (BCLM) is respectively an increasing issue. Recent data found in literature indicates improved survival following liver resection with systemic therapy.
Objective. The aim of study was to evaluate surgical treatment in patients with isolated BCLM.
Materials and method. During 2009–2013, a retrospective study was undertaken and 30 cases analysed. From nearly 2,000 liver resections performed, 11 female patients at the mean age of 59.18 years with BCLM were qualified for surgery.
Results. The median time between primary and secondary treatment was 3.5 years (1–7). One patient (9.1%) presented an extrahepatic lesion – bone metastasis. The left lobe, right lobe and both lobes of the liver were affected, respectively, in 3 (27.3%), 4 (36.4%) and 4 (36.4%) patients. 5 patients (45.5%) presented single hepatic lesion, in contrast to the maximum number of lesions which equalled 6 in the right lobe. Average hospitalisation period was 13.27 days and discharge on the 11.3 postoperative day. One-year survival was 72.7% (8 patients); therefore, three-year survival was 36.4% (4 patients).
Conclusions. Oncological centres should assess BCLM patients more openly and qualify them for hepatic resection along with adjuvant systemic treatment in order to improve overall survival. This, however, needs to be studied in a multicentre randomized trial.
DOI: 10.5604/12321966.1226866
PMID 28030943 - click here to show this article in PubMed
  FULL TEXT STATS

Recommend this article to:

Name:
E-mail:
From:
Language:


Related articles in IndexCopernicus™
     Oncology patients [0 related records]
     Polish women [1 related records]
     liver metastases [21 related records]
     breast cancer [897 related records]



 

Related articles

K Wroński, M Żechowicz,
Primary woman neuroendocrine breast tumor – case...
Primary neuroendocrine breast carcinoma (NEBC) is extremely rare type of breast tumor and has been reported sporadically. Most neuroendocrine tumors are located in the gastrointestinal tract. This type of breast cancer was first time recognized by th...
ABSTRACT
M Kamińska, T Kubiatowski,
Evaluation of symptoms of anxiety and depression ...
Objective. Evaluation of the presence of symptoms of anxiety and depression in women treated for breast cancer who underwent surgical procedure using one of two alternative methods, either radical mastectomy or breast conserving treatment (BCT...
ABSTRACT
, ,
IMPACT OF DESIGNED NURSING PROTOCOL ON BREAST CANC...
Breast cancer is one of the highest malignant tumours which affect females in both developed and developing countries, referring to the recent statistics of the WHO and Cancer Research UK Institute. The role of breast cancer nurse starts from the f...
ABSTRACT